Peel Hunt Reiterates Add Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “add” rating restated by investment analysts at Peel Hunt in a research report issued to clients and investors on Tuesday,London Stock Exchange reports. They currently have a GBX 10 price target on the stock. Peel Hunt’s target price points to a potential upside of 53.85% from the stock’s current price.

Separately, Shore Capital reduced their price target on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of GBX 17.50.

hVIVO Stock Up 3.2%

Shares of hVIVO stock traded up GBX 0.20 during midday trading on Tuesday, hitting GBX 6.50. The company had a trading volume of 2,843,804 shares, compared to its average volume of 2,858,710. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market capitalization of £44.67 million, a P/E ratio of 8.44 and a beta of 0.97. The company has a 50 day moving average of GBX 7.89 and a 200 day moving average of GBX 10.77. hVIVO has a 52-week low of GBX 6.20 and a 52-week high of GBX 29.80.

hVIVO (LON:HVO) last released its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities analysts predict that hVIVO will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.